open access
Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) levels with abnormally high ankle-brachial index in atrial fibrillation
Affiliations- Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
- Department of General Surgery, Surgical Specialties and Organ Transplantation
- Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
- Mediterranea Cardiocentro, Naples, Italy
open access
Abstract
BACKGROUND: High ankle-brachial index (ABI) has been associated with increased risk of worse outcomes in the general population. Few data on atrial fibrillation (AF) do exist. Experimental data suggest that proprotein convertase subtilisin/kexin type 9 (PCSK9) contribute to vascular calcification but clinical data on this association are lacking.
AIMS: We want to investigate the relationship between circulating PCSK9 levels and abnormally high ABI in patients suffering from AF.
METHODS: We analysed data from 579 patients included in the prospective ATHERO-AF study. An ABI ≥1.4 was considered as high. PCSK9 levels were measured coincidentally with ABI measurement. We used an optimized cut-offs of PCSK9 for both ABI and mortality obtained from ROC curve analysis. All-cause mortality according to the ABI value was also analysed.
RESULTS: 115 (19.9%) had an ABI ≥1.4. The mean (SD) age was 72.1 (7.6) years and 42.1% of patients were women. Patients with ABI ≥1.4 were older, more frequently male and diabetic. Multivariable logistic regression analysis showed an association between ABI ≥1.4 and serum levels of PCSK9 >1150 pg/ml (odds ratio [OR], 1.649; 95% confidence interval [CI], 1.047–2.598; P = 0.031). During a median follow up of 41 months, 113 deaths occurred. At multivariable Cox regression analysis, ABI ≥1.4 (hazard ratio [HR], 1.626; 95% CI, 1.024–2.582; P = 0.039), CHA2DS2-VASc score (HR, 1.249; 95% CI, 1.088–1.434; P = 0.002), antiplatelet drug use (HR, 1.775; 95% CI, 1.153–2.733; P = 0.009), and PCSK9 >2060 pg/ml (HR, 2.200; 95% CI, 1.437–3.369; P <0.001) were associated with all-cause death.
CONCLUSIONS: In AF patients, PCSK9 levels relate to an abnormally high ABI ≥1.4. Our data suggest a role for PCSK9 in favouring vascular calcification in AF patients.
Abstract
BACKGROUND: High ankle-brachial index (ABI) has been associated with increased risk of worse outcomes in the general population. Few data on atrial fibrillation (AF) do exist. Experimental data suggest that proprotein convertase subtilisin/kexin type 9 (PCSK9) contribute to vascular calcification but clinical data on this association are lacking.
AIMS: We want to investigate the relationship between circulating PCSK9 levels and abnormally high ABI in patients suffering from AF.
METHODS: We analysed data from 579 patients included in the prospective ATHERO-AF study. An ABI ≥1.4 was considered as high. PCSK9 levels were measured coincidentally with ABI measurement. We used an optimized cut-offs of PCSK9 for both ABI and mortality obtained from ROC curve analysis. All-cause mortality according to the ABI value was also analysed.
RESULTS: 115 (19.9%) had an ABI ≥1.4. The mean (SD) age was 72.1 (7.6) years and 42.1% of patients were women. Patients with ABI ≥1.4 were older, more frequently male and diabetic. Multivariable logistic regression analysis showed an association between ABI ≥1.4 and serum levels of PCSK9 >1150 pg/ml (odds ratio [OR], 1.649; 95% confidence interval [CI], 1.047–2.598; P = 0.031). During a median follow up of 41 months, 113 deaths occurred. At multivariable Cox regression analysis, ABI ≥1.4 (hazard ratio [HR], 1.626; 95% CI, 1.024–2.582; P = 0.039), CHA2DS2-VASc score (HR, 1.249; 95% CI, 1.088–1.434; P = 0.002), antiplatelet drug use (HR, 1.775; 95% CI, 1.153–2.733; P = 0.009), and PCSK9 >2060 pg/ml (HR, 2.200; 95% CI, 1.437–3.369; P <0.001) were associated with all-cause death.
CONCLUSIONS: In AF patients, PCSK9 levels relate to an abnormally high ABI ≥1.4. Our data suggest a role for PCSK9 in favouring vascular calcification in AF patients.
Keywords
ABI, PCSK9, mortality, atrial fibrillation, peripheral artery disease
About this articleTitle
Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) levels with abnormally high ankle-brachial index in atrial fibrillation
Journal
Kardiologia Polska (Polish Heart Journal)
Issue
Article type
Original article
Published online
2023-03-15
Page views
34
Article views/downloads
14
DOI
10.33963/KP.a2023.0067
Pubmed
Keywords
ABI
PCSK9
mortality
atrial fibrillation
peripheral artery disease
Authors
Danilo Menichelli
Gioacchino Galardo
Vittoria Cammisotto
Simona Bartimoccia
Roberto Carnevale
Pasquale Pignatelli
Daniele Pastori
References (39)- Ragusa R, Basta G, Neglia D, et al. PCSK9 and atherosclerosis: Looking beyond LDL regulation. Eur J Clin Invest. 2021; 51(4): e13459.
- Guo Y, Yan B, Tai S, et al. PCSK9: Associated with cardiac diseases and their risk factors? Arch Biochem Biophys. 2021; 704: 108717.
- Pastori D, Nocella C, Farcomeni A, et al. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017; 70(12): 1455–1462.
- Xiang Q, Liu WF, Zeng JL, et al. Effect of PCSK9 on Vascular Smooth Muscle Cell Functions: A New Player in Atherosclerosis. Curr Med Chem. 2021; 28(36): 7446–7460.
- Navarese EP, Kolodziejczak M, Kereiakes DJ, et al. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. Ann Intern Med. 2016; 164(9): 600–607.
- Akers EJ, Nicholls SJ, Di Bartolo BA. Plaque Calcification: Do Lipoproteins Have a Role? Arterioscler Thromb Vasc Biol. 2019; 39(10): 1902–1910.
- Pastori D, Pignatelli P, Sciacqua A, et al. Relationship of peripheral and coronary artery disease to cardiovascular events in patients with atrial fibrillation. Int J Cardiol. 2018; 255: 69–73.
- Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382(9901): 1329–1340.
- Pastori D, Farcomeni A, Milanese A, et al. Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Thromb Haemost. 2020; 120(5): 866–875.
- Anand S, Caron F, Eikelboom J, et al. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2018; 71(20): 2306–2315.
- Kaczmarczyk P, Frołow M, Januszek R, et al. Endothelial function in patients with critical and non-critical limb ischemia undergoing endovascular treatment. Kardiol Pol. 2021; 79(7-8): 804–812.
- Aboyans V, Ricco JB, Bartelink ML. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763–816.
- Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004; 109(6): 733–739.
- Violi F, Davì G, Proietti M, et al. Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. Thromb Haemost. 2016; 115(4): 856–863.
- Pastori D, Farcomeni A, Poli D, et al. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Intern Emerg Med. 2016; 11(2): 199–204.
- Pastori D, Farcomeni A, Saliola M, et al. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. Eur J Intern Med. 2018; 54: 34–39.
- Pastori D, Menichelli D, Del Sole F, et al. Long-Term risk of major adverse cardiac events in atrial fibrillation patients on direct oral anticoagulants. Mayo Clin Proc. 2021; 96(3): 658–665.
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28): 2159–2219.
- Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013; 34(39): 3035–3087.
- McMurray JJ, Adamopoulos S, Anker S. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 14(8): 803–869.
- Pastori D, Menichelli D, Violi F, et al. The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study. Eur J Intern Med. 2021; 85: 80–85.
- Camm A, Kirchhof P, Lip G. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19): 2369–2429.
- Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012; 126(24): 2890–2909.
- Gallego P, Roldán V, Marín F, et al. Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation. Eur J Clin Invest. 2012; 42(12): 1302–1308.
- Velescu A, Clara A, Martí R, et al. Abnormally High Ankle-Brachial Index is Associated with All-cause and Cardiovascular Mortality: The REGICOR Study. Eur J Vasc Endovasc Surg. 2017; 54(3): 370–377.
- Fusaro M, Noale M, Tripepi G, et al. Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: a cross-sectional study using propensity score analysis. Drug Saf. 2013; 36(8): 635–642.
- Okamoto T, Hatakeyama S, Hosogoe S, et al. Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis. PLoS One. 2018; 13(7): e0199160.
- Host LV, Campochiaro C, Afonso A, et al. High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis. Rheumatology (Oxford). 2021; 60(2): 849–854.
- Nogueira RC, Pinheiro LC, Sanches-Lopes JM, et al. Omeprazole induces vascular remodeling by mechanisms involving xanthine oxidoreductase and matrix metalloproteinase activation. Biochem Pharmacol. 2021; 190: 114633.
- Lupo MG, Bressan A, Donato M, et al. PCSK9 promotes arterial medial calcification. Atherosclerosis. 2022; 346: 86–97.
- Alonso R, Mata P, Muñiz O, et al. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis. 2016; 254: 249–253.
- Weijs B, Blaauw Y, Rennenberg RJ, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J. 2011; 32(20): 2555–2562.
- Hasific S, Øvrehus KA, Gerke O, et al. Extent of arterial calcification by conventional vitamin K antagonist treatment. PLoS One. 2020; 15(10): e0241450.
- Eggebrecht L, Prochaska JH, Schulz A, et al. Intake of Vitamin K Antagonists and Worsening of Cardiac and Vascular Disease: Results From the Population-Based Gutenberg Health Study. J Am Heart Assoc. 2018; 7(17): e008650.
- Bakhai A, Petri H, Vahidnia F, et al. Real-world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non-valvular atrial fibrillation patients in England. J Eval Clin Pract. 2021; 27(1): 119–133.
- Xu Ke, Chan NC. Bleeding in patients with atrial fibrillation treated with combined antiplatelet and anticoagulant therapy: time to turn the corner. Ann Transl Med. 2019; 7(Suppl 6): S198.
- Bassand JP, Virdone S, Badoz M, et al. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021; 5(4): 1081–1091.
- Boriani G, Valenti AC, Vitolo M. Biomarkers in atrial fibrillation: a constant search for simplicity, practicality, and cost-effectiveness. Kardiol Pol. 2021; 79(3): 243–245.
- Raal F, Panz V, Immelman A, et al. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013; 2(2): e000028.
